<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02375022</url>
  </required_header>
  <id_info>
    <org_study_id>ZYTOP1501</org_study_id>
    <nct_id>NCT02375022</nct_id>
  </id_info>
  <brief_title>Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations</brief_title>
  <official_title>A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar®) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu Simcere Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beta Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-arm pilot study tries to invesitgate how well giving icotinib with rh-endostatin&#xD;
      (Endostar®) works in treating patients with advanced stage non-small cell lung cancer (NSCLC)&#xD;
      with epidermal growth factor receptor (EGFR) activating mutations. Icotinib may stop the&#xD;
      growth of tumor cells by blocking some of the enzymes needed for cell growth.&#xD;
      Anti-angiogeneiss drug, such as rh-endostatin, can block tumor growth by inhibiting the&#xD;
      ability of tumors to grow new blood vessels and spread. It is not yet known whether icotinib&#xD;
      is more effective when given with rh-endostatin in NSCLC patients with EGFR activating&#xD;
      mutations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Open-label, single-arm, prospective pilot study.&#xD;
&#xD;
        2. Definition of advanced non small cell lung cancer: stage IIIb or IV. EGFR mutation&#xD;
           status: activating mutation (defined as deletion 19 or exon 21 L858R mutation).&#xD;
&#xD;
        3. Before starting study treatment, computed tomography scans of the chest, B ultrasound of&#xD;
           abdomen, 12-lead electrocardiogram, MRI scan of brain, and a bone scan are required.&#xD;
&#xD;
        4. Tumor response, based on investigator-assessed Response Evaluation Criteria in Solid&#xD;
           Tumors (RECIST v.1.1), will be evaluated every 6 weeks during treatment.&#xD;
&#xD;
        5. Exploratory evaluation will be performed using dynamic contrast enhanced MRI (DCE-MRI).&#xD;
&#xD;
        6. QoL will be assessed using the core module, which will be completed by patients at&#xD;
           baseline and before each cycle during treatment.&#xD;
&#xD;
        7. All patients who prematurely discontinue treatment for any reason will be followed for&#xD;
           survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of Participants with Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Endostar and icotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of drug: Endostar: 15mg CIV d1-9, Q3w and icotinib: 125mg TID po. If no progressive disease observed, combination treatment will continue until unacceptable toxicity or progressive disease.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endostar and icotinib</intervention_name>
    <description>Endostar and icotinib are used as combination therapy.</description>
    <arm_group_label>Endostar and icotinib</arm_group_label>
    <other_name>Recombinant Human Endostatin Injection</other_name>
    <other_name>Icotinib Hydrochloride Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic documentation of non small cell lung cancer, with activating epidermal&#xD;
             growth factor receptor (defined as deletion 19 or exon 21 L858R mutation).&#xD;
&#xD;
          -  Stage IV disease according to the 7th Edition of the American Joint Committee on&#xD;
             Cancer staging system -Measureable disease&#xD;
&#xD;
          -  Life expectancy of &gt;= 12 months&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1, 500/mm^3, platelet count &gt;= 100,000/mm^3,&#xD;
             hemoglobin &gt;= 9.0 g/dL.&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x upper limit of normal (ULN), serum glutamic oxaloacetic&#xD;
             transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamic pyruvic&#xD;
             transaminase (SGPT) (alanine aminotransferase [ALT]) =&lt; 2.5 x ULN in patients without&#xD;
             liver or bone metastases; &lt; 5 x ULN in patients with liver or bone metastases,&#xD;
             cockcroft-Gault calculated creatinine clearance of &gt;= 45 ml/min or creatinine =&lt; 1.5 x&#xD;
             ULN.&#xD;
&#xD;
          -  Prothrombin time (PT) =&lt; 1.5 x ULN, partial thromboplastin time (PTT) =&lt; ULN&#xD;
&#xD;
          -  Urine dipstick proteinuria &lt; 2+. Patients discovered to have &gt;= 2 + proteinuria on&#xD;
             dipstick urinalysis at baseline should undergo a 24-hour urine collection and must&#xD;
             demonstrate &lt; 1 g of protein in 24 hours.&#xD;
&#xD;
          -  Negative pregnancy test done =&lt; 7 days prior to randomization, for women of&#xD;
             childbearing potential only.&#xD;
&#xD;
          -  Provide informed written consent.&#xD;
&#xD;
          -  Willing to return to enrolling institution for follow-up.&#xD;
&#xD;
          -  Willing to provide tissue and blood samples for correlative research purposes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  Evidence of central nervous system involvement or brain metastases confirmed by head&#xD;
             CT or brain MRI within 28 days prior to being registered for protocol therapy.&#xD;
&#xD;
          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days&#xD;
             prior to registration for protocol therapy.&#xD;
&#xD;
          -  Anticipation of need for major surgical procedure during the course of the study.&#xD;
&#xD;
          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7&#xD;
             days prior to registration for protocol therapy.&#xD;
&#xD;
          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess&#xD;
             within 6 months prior to registration for protocol therapy.&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  History of hemoptysis.&#xD;
&#xD;
          -  Clinically significant infections as judged by the treating investigator.&#xD;
&#xD;
          -  Other active malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiong Zhao</last_name>
      <phone>0571-87236802</phone>
      <email>doczq.2008@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ling Peng</last_name>
      <phone>0571-87236800</phone>
      <email>Drpengling@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Qiong Zhao</investigator_full_name>
    <investigator_title>Chief, Department of Thoracic Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endostar protein</mesh_term>
    <mesh_term>Endostatins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

